These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 7648647)

  • 61. Nifedipine gastrointestinal therapeutic system: an overview of its antiatherosclerotic effects.
    Ueng KC; Lin MC; Chan KC; Lin CS
    Expert Opin Drug Metab Toxicol; 2007 Oct; 3(5):769-80. PubMed ID: 17916061
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.
    Grundy JS; Foster RT
    Clin Pharmacokinet; 1996 Jan; 30(1):28-51. PubMed ID: 8846626
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [24-hour protection and control: a new era of calcium antagonists. Amlodipine provides 24 hours of efficacy and safety].
    Med Clin (Barc); 1992 Feb; 98(8):suppl 2 p.. PubMed ID: 1532845
    [No Abstract]   [Full Text] [Related]  

  • 64. Calcium antagonists.
    Conti CR; Pepine CJ; Feldman RL; Hill JA
    Cardiology; 1985; 72(5-6):297-321. PubMed ID: 2866840
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pharmacokinetic interactions of nifedipine and quinidine.
    Hippius M; Henschel L; Sigusch H; Tepper J; Brendel E; Hoffmann A
    Pharmazie; 1995 Sep; 50(9):613-6. PubMed ID: 7480098
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparison of two formulations of nifedipine during 24-hour ambulatory blood pressure monitoring--a comment.
    Lucas BD; Hilleman DE; Wurdeman RL
    Pharmacotherapy; 1997; 17(4):853-4. PubMed ID: 9250574
    [No Abstract]   [Full Text] [Related]  

  • 67. Chronotherapy with nifedipine GITS in hypertensive patients: improved efficacy and safety with bedtime dosing.
    Hermida RC; Ayala DE; Mojón A; Fernández JR
    Am J Hypertens; 2008 Aug; 21(8):948-54. PubMed ID: 18600215
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Vasodilating effects of the new calcium antagonist benidipine hydrochloride in anesthetized dogs and cats.
    Karasawa A; Kubo K; Shuto K; Oka T; Nakamizo N
    Arzneimittelforschung; 1988 Nov; 38(11A):1707-12. PubMed ID: 3219145
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Dihydropyridine calcium antagonists and the trough: peak ratio: focus on adverse effects.
    Myers MG
    J Hypertens Suppl; 1994 Nov; 12(8):S73-6; discussion S76-7. PubMed ID: 7707160
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A potential risk of sublingual nifedipine treatment in surgically treated patients in Japan.
    Kobayashi E; Kitoh Y; Fujimura A
    Crit Care Med; 1998 Jul; 26(7):1293. PubMed ID: 9671385
    [No Abstract]   [Full Text] [Related]  

  • 71. Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Nifedipine.
    Gajendran J; Krämer J; Shah VP; Langguth P; Polli J; Mehta M; Groot DW; Cristofoletti R; Abrahamsson B; Dressman JB
    J Pharm Sci; 2015 Oct; 104(10):3289-98. PubMed ID: 26149619
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Protection of infarcting myocardium by slow channel inhibitors. Comparative effects of verapamil, nifedipine, and diltiazem in the coronary-ligated, isolated working rat heart.
    Hamm CW; Opie LH
    Circ Res; 1983 Feb; 52(2 Pt 2):I129-38. PubMed ID: 6831647
    [No Abstract]   [Full Text] [Related]  

  • 73. Evaluation of the method for nifedipine administration for a rapid onset of clinical effect: a clinical study in normal volunteers.
    Kubota R; Komiyama T; Shimada H
    Yakugaku Zasshi; 2001 May; 121(5):355-64. PubMed ID: 11360489
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Selective improvement in subendocardial perfusion distal to a flow-limiting coronary artery stenosis: effects of the new calcium channel blocking agent, FR 34235, nifedipine and diltiazem.
    Gross GJ; Warltier DC
    J Pharmacol Exp Ther; 1984 Mar; 228(3):531-6. PubMed ID: 6707908
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine.
    Elliott HL; Meredith PA
    Postgrad Med J; 1991; 67 Suppl 3():S20-3. PubMed ID: 1836870
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Myocardial perfusion distal to an acute or chronic coronary artery occlusion: effects of diltiazem and nifedipine.
    Zyvoloski MG; Brooks HL; Gross GJ; Warltier DC
    J Pharmacol Exp Ther; 1982 Aug; 222(2):494-500. PubMed ID: 7097568
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Dose-response relation of gallopamil in comparison with nifedipine, diltiazem and tiapamil in patients with coronary heart disease].
    Hopf R; Fleischer K; Forster A; Mohler C; Schulz PC; Kaltenbach M
    Z Kardiol; 1989; 78 Suppl 5():69-76. PubMed ID: 2698566
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Amlodipine versus nifedipine retard in the treatment of chronic ischemic heart disease.
    Circo A; Scaccianoce G; Platania F; Castelli D; Cardillo R; Mangiameli S
    Clin Ter; 1992 Jan; 140(1):43-57. PubMed ID: 1388115
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [A rare case of nifedipine bezoar].
    Jarry J; Sassoust G
    Presse Med; 2008 Mar; 37(3 Pt 1):428-30. PubMed ID: 18164899
    [No Abstract]   [Full Text] [Related]  

  • 80. Prolonged QT interval and ventricular fibrillation after treatment with sublingual nifedipine for malignant hypertension.
    Peters FP; de Zwaan C; Kho L
    Arch Intern Med; 1997 Dec 8-22; 157(22):2665-6. PubMed ID: 9531240
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.